Watch the self-injection demonstration videos. Injection training support is always available. Full storage instructions are available in the Medication Guide. If more comfortable, take your HUMIRA Pen or prefilled syringe out of the refrigerator 15 to 30 minutes before injecting to allow the liquid to reach room temperature. Do not use if the liquid is cloudy or discolored or has flakes or particles in it.
Injection is complete when the yellow indicator fully appears in the window view and stops moving. The prefilled syringe is glass. These are not complete injection instructions. What to do if you miss a dose. From doorbell to disposal. Need help reviewing insurance coverage options?
This Comparison Chart Can Help. You have many treatment options. Your doctor will work with you to find the best one. An intramuscular injection is a technique used to deliver a medication deep into the muscles. This allows the medication to be absorbed quickly. For small amounts of delicate drugs, a subcutaneous injection can be a convenient way of getting a medication into your body.
When a medication is injected directly into muscle, it is called an intramuscular injection IM. The Z-track method of IM is used to prevent tracking…. Curious about ventrogluteal injections? Learn why this is one of the safest types of intramuscular injection and how to do it.
When you are in pain and fatigued, finding foods that are both nourishing and easy to prepare is particularly essential. Psoriatic arthritis is a type of arthritis that affects some people with psoriasis. Learn about its early signs and symptoms. Some natural remedies may be able to ease your psoriatic arthritis joint pain. Turmeric, acupuncture, and vitamin D are just three of many you can try….
Psoriatic arthritis is a type of arthritis that only occurs in people with psoriasis. Learn more about the types and causes of psoriatic arthritis and…. Psoriatic arthritis can affect several parts of your body, including your nails. Learn about some of the effects of psoriatic arthritis on your nails. Finding a diet that helps me keep my psoriatic arthritis symptoms in check has been a journey.
Health Conditions Discover Plan Connect. Medically reviewed by Deborah Weatherspoon, Ph. Procedure Dosage Tips Missed doses Outlook Overview Adalimumab Humira is an injectable medication people use to treat several conditions. How to inject Humira. Tips for injection. What should you do if you miss a dose? Individuals who previously self-injected any agent or who were using other biological agents were excluded.
All injections were subcutaneous, were in the same part of the body, and were performed on the same day day 0. Immediately after using each device, patients answered a questionnaire assessing the hand used to self-inject left, right, both , ease of use for self-injection extremely easy, easy, neither easy nor difficult, difficult, or extremely difficult , overall discomfort none, mild, moderate, severe, or such discomfort that I cannot inject future doses , and overall impression of the self-injection experience extremely favorable, favorable, neither favorable nor unfavorable, unfavorable, or extremely unfavorable.
After completing all 4 injections, patients completed a questionnaire on their preference for the devices prefilled syringe, autoinjector, or undecided. Adverse events were considered serious if they resulted in death, were life threatening, required hospitalization or prolongation of an existing inpatient hospitalization, resulted in a persistent or significant disability or incapacity, were a congenital abnormality or birth defect, were cancer, were associated with an overdose, or were any other important medical event.
All included patients provided written informed consent. A power calculation was not performed. Instead, a study size estimate of subjects was planned based on sample sizes that yielded relevant results in similar studies. The primary outcome measure device preference was analyzed in the per-protocol set, defined as all subjects who met the inclusion and exclusion criteria, received all 4 injections, and completed the device preference questionnaire.
Statistical analyses of preference included frequency distribution overall immediately and 2 weeks after injection; by order of device administration; 2 weeks after injection by preference immediately after injection; and by age, sex, ethnicity, marital status, education level, employment status, and total Mayo score category. Statistical analysis of secondary outcome measures ease of use, discomfort, and overall impression included frequency distribution overall and by order of injection.
Missing data were not replaced. Calculations were made using SAS version 9. Between July 11, , and September 17, , patients were included in the study, and the study was completed on October 5, Of the recruited patients, 99 were treated. Another 8 patients did not fulfill the selection criteria.
Thus, 91 patients were included in the analysis. On average, patients had been diagnosed with UC for 8. Most were being treated with 5-aminosalicylic acid and corticosteroids, and most had not previously received anti-TNF therapy.
Immediately after injections, approximately three-quarters of patients This was similar to the preference reported 2 weeks later, with This was also the case irrespective of the order of injection, although more patients who started with the autoinjector preferred it Also, most patients Results were similar when analyzed for all 99 patients completing the questionnaire data not shown. Notes: Patient preference for the different devices was assessed immediately after the injections and 2 weeks later.
A Device preference according to order of presentation immediately after the injections. B Device preference according to order of presentation 2 weeks after the injections. C Device preference at week 2 according to preference immediately after the injections. D Device preference immediately after the injections according to age group.
E Device preference immediately after the injections according to Mayo score at baseline. More patients considered the autoinjector extremely easy or easy to use Moderate discomfort or worse was reported by only 5 patients 5. Severe discomfort or discomfort such that the patient could not inject future doses was reported by 8 patients 8.
In agreement with these findings, An unfavorable impression of the device or worse was reported by only 2 patients 2. The order of use of the 2 different devices appeared to slightly bias the subjects toward the device they used first.
For example, the proportion of patients with an extremely favorable or favorable impression of the autoinjector was Likewise, the proportion of patients with an extremely favorable or favorable impression of the prefilled syringe was None of the patients experienced a serious adverse event. Treatment-emergent adverse events, all mild or moderate in severity, were reported by 10 patients This study showed that most patients with moderate-to-severe UC preferred to self-administer golimumab with the autoinjector over a prefilled syringe.
More patients found the autoinjector easier to use and to less often cause discomfort than the prefilled syringe. This preference for the autoinjector did not change when measured again 2 weeks later, during which time most delayed reactions would have appeared.
Demographic characteristics did not significantly affect preference. Order of presentation did not affect the overall preference for the autoinjector, although it biased the preference somewhat toward the device first presented.
The results of this study are strengthened by the fact that data were collected in a real-life clinical setting at multiple sites. In addition, although the absolute sample size was small, this study included a relatively large population for UC and was enough to observe meaningful differences in preference.
Overall opinions were also favorable in the GO-MORE trial, in which patients with active RA self-injected or had someone else administer subcutaneous golimumab with the same device. Most of the patients in the GO-MORE study who used the autoinjector had a favorable impression of it, considered it easy to use, and reported that it caused little pain or discomfort.
However, the study did not directly assess preference or compare patient experiences between the autoinjector and injection with the prefilled syringe. A preference for the golimumab autoinjector over previous injection devices was also reported by Prefilled pens or other autoinjectors are also preferred over and considered easier to use and less painful than syringes for self-administration of darbepoetin by chronic kidney disease patients, 11 methotrexate 13 and adalimumab 14 for RA patients, and insulin for diabetes patients.
A systematic review in found that treatment adherence to anti-TNF biologics in UC patients was only Although the SmartJect autoinjector might therefore be expected to improve adherence to golimumab, we did not assess adherence in this study. This study showed that patients with UC generally prefer to administer golimumab with an autoinjector.
0コメント